Appointment of Oleg Nodelman to the board enhances strategic oversight, bringing over two decades of investment management experience specifically in the biotech sector. Nodelman's role as the largest ...

Zymeworks Inc., a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for challenging diseases like cancer, inflammation, and autoimmune disorders, has announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced ...

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...

View Zymeworks Inc. ZYME stock quote prices, financial information, real-time forecasts, and company news from CNN.

So it's my pleasure to have with me the CEO of Zymeworks, Ken Galbraith. Welcome. Thank you so much. So welcome to those in the room and those listening online. I'm Yigal Nochomovitz. I'm covering ...

Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro. Zymework, along with its partners, ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Zymeworks Inc. (ZYME) reports results for the quarter ended September 2025. While this widely-known consensus outlook ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

On Wednesday, Zymeworks Inc. (NASDAQ:ZYME) released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents. Sales came at ...